IGF-1 LR3
Unapproved long-acting IGF-1 analog — not FDA-approved.
What it's for
IGF-1 LR3 is a lab-made research version of IGF-1 (insulin-like growth factor 1), tweaked so it may last longer and bind less tightly to the blood proteins that normally buffer IGF-1. It is not an FDA-approved medicine.
What it does for the body
In research settings it is discussed for strong IGF-1–like growth and repair signaling. It is not FDA-approved to treat any human disease. An approved IGF-1 medicine for a rare pediatric use is mecasermin — a different product. This guide sticks to what published research and regulators actually support.
What it targets
It is meant to turn on the IGF-1 growth receptor on cells, which can encourage growth-and-repair messages inside the cell. The LR3 design is researched for weaker buffering by IGF-binding proteins, so more of the signal may stay available — still experimental, not proven like an approved drug.
Research context
Bottom line for readers: IGF-1 LR3 is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.
Studied for (literature interest)
- Bones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: IGF-1 LR3 — FDA.gov search
- ClinicalTrials.gov search: IGF-1 LR3 — U.S. clinical trials registry
- Drugs@FDA search: IGF-1 LR3 — FDA drug database (if approved)
- PubMed search: IGF-1 LR3 — NCBI PubMed
- PubMed Central search: IGF-1 LR3 — NCBI PMC